乳腺癌患者血清中可溶性白细胞介素-2受体的测定

Study on Serum SIL 2R Levels in Patients with Breast Cancer

应用双抗体夹心酶联免疫吸附（ＥＬＩＳＡ）法同批对５０例乳腺癌患者，３０例乳腺腺瘤患者及４０例正常人的血清可溶性白细胞介素２受体（ｓｏｌｕｂｌｅｉｎｔｅｒｌｅｕｋｉｎ２ｒｅｃｅｐｔｏｒ，ｓＩＬ２Ｒ）进行了检测。结果显示，乳腺癌患者的血清ｓＩＬ２Ｒ水平明显高于乳腺腺瘤患者及正常对照组，统计学上具有极显著差异（Ｐ＜００１）；乳腺癌根治术后２０天的ｓＩＬ２Ｒ水平较术前明显下降，与正常人群对照无明显差异（Ｐ＞００５），但术后７天的ｓＩＬ２Ｒ水平下降不明显，与术前水平接近（Ｐ＞００５），乳腺癌患者的术前ｓＩＬ２Ｒ水平与临床分期关系密切，Ⅲ期患者明显高于Ⅰ、Ⅱ期者（Ｐ＜００１），而与病理类型无明显关系。上述结果提示，血清ｓＩＬ２Ｒ测定可作为鉴别乳腺癌和乳腺良性肿物及判断乳腺癌病情。

Using the method of sandwich ELISA,we studied the mean levels of serum sIL 2R in 50 patients with breast cancer.At the same time,we also detected 30 patients with breast benign tumor and 40 of normal individuals.The results showed that the serum sIL 2R levels in the patients with breast cancer were much higher than that of breast benign tumor and the controls (P<0 01).Serum sIL 2R level decreased significantly at 20 days after radical operation for breast cancer,with no remarkably difference to the healthy human (P>0.05),but the serum sIL 2R of 7 days after radical operation for breast cancer was similar to that of pre operater.The serum sIL 2R level was relative to the clinical stage of breast cancer,but was not relative to the pathology.It can be concluded that serum sIL 2R assay is a new biological marker for the assessment of the stage,the observation of therapeutical effect and the prognosis in breast cancer.